4.6 Review

Comorbidities in Patients with Psoriasis

Journal

AMERICAN JOURNAL OF MEDICINE
Volume 122, Issue 12, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2009.06.021

Keywords

Cardiovascular disease; Metabolic syndrome; Psoriasis; Psoriatic arthritis comorbidities

Funding

  1. Amgen
  2. Centocor, Inc
  3. Wyeth Pharmaceuticals
  4. Immune Control
  5. Celgene Corp
  6. Pharmacare
  7. Incyte
  8. Novo Nordisk
  9. Pfizer
  10. Abbott

Ask authors/readers for more resources

Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities. Patients with psoriasis have been shown to have an increased incidence of metabolic syndrome and cardiovascular disease compared with the general population. The chronic inflammatory nature of psoriasis has been suggested to be a contributing and potentially independent risk factor for the development of cardiovascular comorbidities. Understanding the interrelationship between these conditions is important for the management of psoriasis and the associated comorbidities. This review will focus on the range of comorbidities associated with psoriasis, with emphasis on cardiometabolic conditions and the aim of encouraging primary care physicians to screen psoriatic patients for cardiometabolic disorders and risk factors. (C) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, 1150.e1-1150.e9

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available